<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037227</url>
  </required_header>
  <id_info>
    <org_study_id>COVID19-0421</org_study_id>
    <nct_id>NCT05037227</nct_id>
  </id_info>
  <brief_title>Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged &gt;18 Years in Indonesia</brief_title>
  <official_title>Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged &gt;18 Years in Indonesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is evaluating safety profile of COVID-19 Vaccine in healthy adults aged&#xD;
      &gt;18 years in Indonesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess any serious systemic reaction within 30 minutes after COVID-19 vaccine&#xD;
      immunization.&#xD;
&#xD;
      To assess systemic reaction after COVID-19 Vaccine immunization. To assess local reaction&#xD;
      after COVID-19 Vaccine immunization. To assess any serious adverse event after COVID-19&#xD;
      Vaccine immunization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">October 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Any serious adverse event occurring from inclusion until 30 minutes after the injection</measure>
    <time_frame>Within 30 minutes after vaccination</time_frame>
    <description>Number and percentage of subjects with serious systemic reactions 30 minutes after immunization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local reaction and systemic events occurring within 30 minutes after each immunization.</measure>
    <time_frame>Within 30 minutes after vaccination</time_frame>
    <description>Number and percentage of subjects with at least one of these adverse events, solicited or not, within 30 minutes after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local reaction and systemic events occurring within 28 days after immunization</measure>
    <time_frame>28 days</time_frame>
    <description>Number and percentage of subjects with at least one of these adverse events, solicited or not, within 28 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any serious adverse event during observation period.</measure>
    <time_frame>28 days</time_frame>
    <description>Number and percentage of subjects with serious adverse event from inclusion until 28 day after vaccination.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Safety Issues</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study is involving healthy adults aged &gt; 18 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically healthy adults aged &gt; 18 years.&#xD;
&#xD;
          -  Subjects have been informed properly regarding the study and signed the informed&#xD;
             consent form.&#xD;
&#xD;
          -  Subjects will commit to comply with the instructions of the investigator and the&#xD;
             schedule of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects concomitantly enrolled or scheduled to be enrolled in another trial.&#xD;
&#xD;
          -  Evolving mild, moderate or severe illness, especially infectious disease or fever&#xD;
             (body temperature ≥37.5℃, measured with thermometer).&#xD;
&#xD;
          -  Women who are lactating, pregnant or planning to become pregnant during the study&#xD;
             period.&#xD;
&#xD;
          -  History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular&#xD;
             injection.&#xD;
&#xD;
          -  Subjects who have any history of confirmed or suspected immunosuppressive or&#xD;
             immunodeficient state, or received in the previous 4 weeks a treatment likely to alter&#xD;
             the immune response (intravenous immunoglobulins, blood-derived products or long-term&#xD;
             corticosteroid therapy (&gt; 2 weeks)).&#xD;
&#xD;
          -  Subjects receive any vaccination within 1 month before and after IP immunization.&#xD;
&#xD;
          -  Subjects plan to move from the study area before the end of study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julitasari Sundoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indonesian Vaccine Safety Advisory Commitee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julitasari Sundoro, MD</last_name>
    <phone>+62818191147</phone>
    <email>komnasppkipi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jakarta Provincial Ministry of Health</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julitasari Sundoro, MD</last_name>
      <phone>+62818191147</phone>
      <email>komnasppkipi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

